DNA based early detection of Nasopharyngeal Carcinoma (NPC)

Many patients do not have any signs and symptoms until NPC reaches an advanced stage. Many patients are unable to recognize their sickness and receive treatment at the optimal time.
Statistics figures show that approximately 80% of unscreened patients are diagnosed with advanced NPC1.
Up to now, there is no vaccination for the prevention of NPC as a type of virus-associated cancer. Early screening is one of the best ways to prevent NPC. It could greatly increase the chance of successful treatment as well.

1. Chan KCA, Woo JKS, King A, et al. Analysis of Plasma Epstein-Barr virus DNA to Screen for Nasopharyngeal Cancer. N Engl J Med. 2017;377(6):513-522. doi:10.1056/NEJMoa1701717.

Product Code: NPC_DNA
i h

Product Details:


  • Non-invasive. Requires blood sample only
  • High accuracy (>97% sensitivity)2
  • With the combined use of Polymerase Chain Reaction (PCR) and state-of-the-art Next-generation Sequencing (NGS) technologies, the circulating DNA in the blood plasma can be examined thoroughly. Data are then analyzed and interpreted using advanced computer algorithms
  • Demonstrate low false-positive rate (0.7%)2 (false-positive rate of EBV serology test: 40%)3,4
  • Invented and clinically validated by a world-class genetic research team of the Chinese University of Hong Kong1,2


  • It has been clinically proven for detecting NPC early among asymptomatic individuals
  • NPC patients identified at an early stage receive a better treatment outcome and a higher chance of survival

Reporting Time
Around 3-7 working days

Risk factors of Nasopharyngeal Cancer (NPC):

  • Living in the southern part of China and Southeast Asia
  • Person aged over 40
  • Having smoking habit
  • Having a diet rich in salt-cured food
  • Frequently exposing to other carcinogens
  • With family history of NPC
  • Infection of Epstein-Barr virus (EBV)
  • Working under conditions rich in formaldehyde (a chemical known as a health hazard) or other chemicals

If you have any of the factors mentioned above, please stay alert and seek advice from a healthcare professional.

2. Lam WKJ, Jiang P, Chan KCA, et al. Sequencing- based counting and size profiling of plasma Epstein- Barr virus DNA enhances population screening of nasopharyngeal carcinoma. Proc Natl Acad Sci U S A. 2018;115(22):E5115-E5124. doi:110. 1073/pnas.1804184115. 
3. Chang KP, Hsu CL, Chang YL, et al. Complementary serum test of antibodies to Epstein-Barr virus nuclear antigen-1 and early antigen: A possible alternative for primary screening of nasopharyngeal carcinoma. Oral oncology. 2008;44(8):784-792. doi:10.1016/j.oraloncology.2007.10.003.
4. Tay JK, Lim MY, Kanagalingam J. Screening in Nasopharyngeal Carcinoma: Current Strategies and Future Directions. Current Reports. 2013;2(1):1-7. doi:10.1007/s40136-013-0035-4.